logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea To Discuss NORTHERA NDA For Treatment Of Symptomatic Neurogenic OH

Chelsea Therapeutics International, Ltd. (CHTP) said it will meet with the Food and Drug Administration's, or FDA's, Cardiovascular and Renal Drugs Advisory Committee on February 23, 2012 to review clinical data in support of the New Drug Application, or NDA, for NORTHERA (droxidopa).

Chelsea is seeking approval of NORTHERA for treating symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Simon Pedder, president and CEO of Chelsea, stated, "We have closely reviewed the materials prepared by the FDA, and look forward to presenting our clinical data to the Advisory Committee, which we believe will address the questions raised by the FDA. We believe that our clinical program has established robust safety and efficacy data for NORTHERA in this patient population."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Air Canada plans to add three U.S. routes next year, to cities San Antonio, Memphis and Savannah, the airline announced. The company said it will launch six new non-stop U.S. services beginning Spring 2017. Harry Potter and the Cursed Child is the best-selling book of 2016 overall and in the Kids & Teens category, confirming the ongoing demand for Harry Potter, Amazon announced. The book, by J.K. Rowling, Jack Thorne and John Tiffany, is also this year's Most Wished For and Most Gifted book. Airline industry profits in 2016 are now expected to be slightly lower than previous view, yet would reach a peak of $35.6 billion, the International Air Transport Association or IATA said Thursday. Meanwhile, profits would decline in 2017 amid overcapacity, rising fuel costs and political turmoil.
comments powered by Disqus
Follow RTT